<DOC>
	<DOCNO>NCT00001090</DOCNO>
	<brief_summary>To evaluate safety immunogenicity live recombinant canarypox ALVAC-HIV vCP205 combination recombinant human granulocyte-macrophage colony-stimulating factor ( GM-CSF ) 80 microg 250 microg . [ AS PER AMENDMENT 4/30/99 : To study safety follow 4 ALVAC immunization nucleic acid gag/pol HIV-1 immunogen ( APL-400-047 , Wyeth-Lederle ) . To assess ability sequence immunization boost LTL , T-helper cell , antibody response . ] ALVAC-HIV candidate vaccine induce HIV-specific CTL responses half recipient protocol . Depending HIV-1 gene product express particular ALVAC-HIV candidate vaccine , volunteer generate anti-Envelope ( vCP125 , vCP205 , vCP300 ) , anti-Gag ( vCP205 vCP300 ) , anti-Nef ( vCP300 ) CTL activity . Although 3 4 immunization different ALVAC-HIV experimental vaccine induce anti-HIV-1 neutralizing antibody portion , often majority , volunteer , geometric mean titer antibodies modest , usually less 50 . This study determine whether increase anti-HIV antibody titer GM-CSF use adjuvant ALVAC-HIV vCP205 also examine kinetics magnitude HIV-specific CTL response .</brief_summary>
	<brief_title>A Multicenter , Randomized , Placebo-Controlled , Double-Blinded , Phase I Trial Evaluate Safety Immunogenicity Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF Healthy , HIV-1 Uninfected Volunteers</brief_title>
	<detailed_description>ALVAC-HIV candidate vaccine induce HIV-specific CTL responses half recipient protocol . Depending HIV-1 gene product express particular ALVAC-HIV candidate vaccine , volunteer generate anti-Envelope ( vCP125 , vCP205 , vCP300 ) , anti-Gag ( vCP205 vCP300 ) , anti-Nef ( vCP300 ) CTL activity . Although 3 4 immunization different ALVAC-HIV experimental vaccine induce anti-HIV-1 neutralizing antibody portion , often majority , volunteer , geometric mean titer antibodies modest , usually less 50 . This study determine whether increase anti-HIV antibody titer GM-CSF use adjuvant ALVAC-HIV vCP205 also examine kinetics magnitude HIV-specific CTL response . In randomized , placebo-controlled , double-blinded study volunteer receive ALVAC-HIV vCP205 10^6.3 TCID50 placebo GM-CSF placebo intramuscular injection Months 0 , 1 , 3 , 6 follow : Group A : vCP205 plus GM-CSF placebo ( 10 volunteer ) Group B : vCP205 plus 80 microg GM-CSF ( 10 volunteer ) Group C : vCP205 plus 250 microg GM-CSF ( 10 volunteer ) Group D : vcP205 placebo plus GM-CSF placebo ( 6 volunteer ) . [ AS PER AMENDMENT 04/30/99 : Boosting APL-400-047 HIV-1 gag/pol DNA add volunteer receive scheduled immunization original protocol . Volunteers Groups A , B , C receive booster intramuscular injection DNA vaccine Months 0 1 , Group D receive DNA control ( bupivacaine carrier alone ) Months 0 1 ] .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Volunteers must : Negative ELISA HIV within 8 week prior immunization . CD4 count 400 cells/mm3 high . Normal history physical examination . Viable EBV line prior initial immunization . [ AS PER AMENDMENT 4/30/99 : Negative antidsDNA antibody ( volunteer receive booster vaccine ) . ] Exclusion Criteria Coexisting Condition : Volunteers follow condition symptom exclude : Medical psychiatric condition occupational responsibility preclude compliance protocol . Recent suicidal ideation psychosis . Active syphilis . NOTE : If serology document false positive due remote ( great 6 month ) treat infection , volunteer eligible . Active tuberculosis . NOTE : Volunteers positive PPD normal chest xray show evidence TB require INH therapy eligible . Positive hepatitis C antibody hepatitis B surface antigen . Allergy egg , neomycin , thimerosal . [ AS PER AMENDMENT 4/30/99 : Hypersensitivity bupivacaine amidetype anesthetic ( e.g. , lidocaine , mepivacaine ) volunteer receive booster vaccine ) . ] Concurrent Medication : Excluded : Lithium cimetidine . Volunteers follow prior condition exclude : History immunodeficiency , chronic illness , autoimmune disease . History cancer unless surgical excision reasonable assurance cure . History suicide attempt past psychosis . History anaphylaxis serious adverse reaction vaccine . History serious allergic reaction substance require hospitalization emergent care ( e.g. , StevensJohnson syndrome , bronchospasm , hypotension ) . [ AS PER AMENDMENT 11/13/97 : History cardiac disease cardiac arrhythmia . ] Prior Medication : Excluded : Live attenuate vaccine within 60 day study . NOTE : Medically indicate subunit kill vaccine ( e.g. , influenza , pneumococcal ) exclusionary , give least 2 week away HIV immunization . Experimental agent within 30 day prior study . Blood product immunoglobulin past 6 month . HIV1 vaccine placebo part previous HIV vaccine trial . Immunosuppressive medication . Risk Behavior : Excluded : Volunteers identifiable higherrisk behavior HIV infection ( i.e. , AVEG Risk Group C D ) , include history injection drug use within 12 month prior enrollment higherrisk sexual behavior define AVEG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Reference Values</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>AIDS Vaccines</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Dose-Response Relationship , Immunologic</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
</DOC>